Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial

Galia Jacobson, Ronen Fluss, Amira Dany-BenShushan, Talia Golan, Tikva Meron, Camilla Zimmermann, Laura A Dawson, Aisling Barry, Marcin Miszczyk, Michael Buckstein, Dayssy Diaz Pardo, Artur Aguiar, Liat Hammer, Adam P Dicker, Maoz Ben-Ailan, Ofir Morag, David Hausner, Zvi Symon, Yaacov R Lawrence, Galia Jacobson, Ronen Fluss, Amira Dany-BenShushan, Talia Golan, Tikva Meron, Camilla Zimmermann, Laura A Dawson, Aisling Barry, Marcin Miszczyk, Michael Buckstein, Dayssy Diaz Pardo, Artur Aguiar, Liat Hammer, Adam P Dicker, Maoz Ben-Ailan, Ofir Morag, David Hausner, Zvi Symon, Yaacov R Lawrence

Abstract

Introduction: Pancreatic cancer is characterised by severe mid-back and epigastric pain caused by tumour invasion of the coeliac nerve plexus. This pain is often poorly managed with standard treatments. This clinical trial investigates a novel approach in which high-dose radiation (radiosurgery) is targeted to the retroperitoneal coeliac plexus nerve bundle. Preliminary results from a single institution pilot trial are promising: pain relief is substantial and side effects minimal. The goals of this study are to validate these findings in an international multisetting, and investigate the impact on quality of life and functional status among patients with terminal cancer.

Methods and analysis: A single-arm prospective phase II clinical trial. Eligible patients are required to have severe coeliac pain of at least five on the 11-point BPI average pain scale and Eastern Cooperative Oncology Group performance status of two or better. Non-pancreatic cancers invading the coeliac plexus are also eligible. The intervention involves irradiating the coeliac plexus using a single fraction of 25 Gy. The primary endpoint is the complete or partial pain response at 3 weeks. Secondary endpoints include pain at 6 weeks, analgesic use, hope, qualitative of life, caregiver burden and functional outcomes, all measured using validated instruments. The protocol is expected to open at a number of cancer centres across the globe, and a quality assurance programme is included. The protocol requires that 90 evaluable patients" be accrued, based upon the assumption that a third of patients are non-evaluable (e.g. due to death prior to 3-weeks post-treatment assessment, or spontaneous improvement of pain pre-treatment), it is estimated that a total of 120 patients will need to be accrued. Supported by Gateway for Cancer Research and the Israel Cancer Association.

Ethics and dissemination: Ethic approval for this study has been obtained at eight academic medical centres located across the Middle East, North America and Europe. Results will be disseminated through conference presentations and peer-reviewed publications.

Trial registration number: NCT03323489.

Keywords: adult palliative care; cancer pain; pain management; radiation oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Model of how radiosurgical intervention is hypothesised to impacts patient well-being. QOL, quality of life.
Figure 2
Figure 2
Trial schema. QOL, quality of life.Q0L: Quality Of Life
Figure 3
Figure 3
Coeliac plexus target deliniation anterior and medial aspects of the aorta contoured from top of T12 to bottom of L2, a surrogate structure for the coeliac plexus (yellow structure).

References

    1. Kelsen DP, Portenoy RK, Thaler HT, et al. . Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995;13:748–55. 10.1200/JCO.1995.13.3.748
    1. Lakatos G, Balázs A, Kui B, et al. . Pancreatic cancer: multicenter prospective data collection and analysis by the Hungarian pancreatic Study Group. J Gastrointestin Liver Dis 2016;25:219–25. 10.15403/jgld.2014.1121.252.pcr
    1. Gencer D, Kästle-Larralde N, Pilz LR, et al. . Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie 2009;32:380–6. 10.1159/000218355
    1. Grahm AL, Andrén-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997;58:542–9. 10.1159/000201499
    1. Arthur AE, Delk A, Demark-Wahnefried W, et al. . Pancreatic cancer survivors' preferences, barriers, and facilitators related to physical activity and diet interventions. J Cancer Surviv 2016;10:981–9. 10.1007/s11764-016-0544-5
    1. Müller-Nordhorn J, Roll S, Böhmig M, et al. . Health-Related quality of life in patients with pancreatic cancer. Digestion 2006;74:118–25. 10.1159/000098177
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30. 10.3322/caac.21332
    1. Ferlay J, Colombet M, Soerjomataram I, et al. . Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356–87. 10.1016/j.ejca.2018.07.005
    1. Wu W, He X, Yang L, et al. . Rising trends in pancreatic cancer incidence and mortality in 2000-2014. Clin Epidemiol 2018;10:789–97. 10.2147/CLEP.S160018
    1. Cherny NI. How to deal with difficult pain problems. Ann Oncol 2005;16 Suppl 2:ii79–87. 10.1093/annonc/mdi705
    1. Lahoud MJ, Kourie HR, Antoun J, et al. . Road map for pain management in pancreatic cancer: a review. World J Gastrointest Oncol 2016;8:599. 10.4251/wjgo.v8.i8.599
    1. Brelin S, Fredheim OM, Loge JH, et al. . Opioids for outpatients with cancer in their last year of life: a nationwide pharmacoepidemiological study. J Opioid Manag 2016;12:25–36. 10.5055/jom.2016.0309
    1. Arcidiacono PG, Calori G, Carrara S, et al. . Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011;3:CD007519. 10.1002/14651858.CD007519.pub2
    1. Levy MJ, Wiersema MJ. EUS-guided celiac plexus neurolysis and celiac plexus block. Gastrointest Endosc 2003;57:923–30. 10.1016/S0016-5107(03)70036-4
    1. Zhu Z, Friess H, diMola FF, et al. . Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 1999;17:2419. 10.1200/JCO.1999.17.8.2419
    1. Kambadakone A, Thabet A, Gervais DA, et al. . Ct-Guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics 2011;31:1599–621. 10.1148/rg.316115526
    1. Mercadante S. Celiac plexus block versus analgesics in pancreatic cancer pain. Pain 1993;52:187–92. 10.1016/0304-3959(93)90130-H
    1. Wong GY, Schroeder DR, Carns PE, et al. . Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092–9. 10.1001/jama.291.9.1092
    1. Kanno Y, Koshita S, Masu K, et al. . Efficacy of EUS-guided celiac plexus neurolysis compared with medication alone for unresectable pancreatic cancer in the oxycodone/fentanyl era: a prospective randomized control study. Gastrointest Endosc 2020;92:120–30. 10.1016/j.gie.2020.01.011
    1. Burris HA, Moore MJ, Andersen J, et al. . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–13. 10.1200/JCO.1997.15.6.2403
    1. Conroy T, Desseigne F, Ychou M, et al. . Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med Overseas Ed 2011;364:1817–25. 10.1056/NEJMoa1011923
    1. Beesley VL, Wockner LF, O'Rourke P, et al. . Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Support Care Cancer 2016;24:3589–99. 10.1007/s00520-016-3212-4
    1. Morganti AG, Trodella L, Valentini V, et al. . Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care 2003;19:258–62. 10.1177/082585970301900407
    1. Wolny-Rokicka E, Sutkowski K, Grządziel A, et al. . Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: a retrospective analysis of single-institutional experiences. Mol Clin Oncol 2016;4:1088–92. 10.3892/mco.2016.851
    1. Wong AA, Delclos ME, Wolff RA, et al. . Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. Am J Clin Oncol 2005;28:227–33. 10.1097/01.coc.0000145290.06582.c3
    1. Zimmermann FB, Jeremic B, Lersch C, et al. . Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas. Hepatogastroenterology 2005;52:246–50.
    1. Lawrence YR, Hammer L, Morag O, et al. . Abstract CT147: celiac plexus radiosurgery a new palliative modality for upper gastrointestinal malignancies-final quality of life results from a proof-of-concept clinical trial. AACR, 2019.
    1. Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med 2003;10:390–2. 10.1197/aemj.10.4.390
    1. Paice JA, Cohen FL. Validity of a verbally administered numeric rating scale to measure cancer pain intensity. Cancer Nurs 1997;20:88–93. 10.1097/00002820-199704000-00002
    1. Ahlers SJGM, van Gulik L, van der Veen AM, et al. . Comparison of different pain scoring systems in critically ill patients in a general ICU. Crit Care 2008;12:R15–18. 10.1186/cc6789
    1. Holdgate A, Asha S, Craig J, et al. . Comparison of a verbal numeric rating scale with the visual analogue scale for the measurement of acute pain. Emerg Med 2003;15:441–6. 10.1046/j.1442-2026.2003.00499.x
    1. Feldman DB, Rand KL, Kahle-Wrobleski K. Hope and goal attainment: testing a basic prediction of hope theory. J Soc Clin Psychol 2009;28:479–97. 10.1521/jscp.2009.28.4.479
    1. Pelayo-Alvarez M, Perez-Hoyos S, Agra-Varela Y. Reliability and concurrent validity of the palliative outcome scale, the Rotterdam symptom checklist, and the brief pain inventory. J Palliat Med 2013;16:867–74. 10.1089/jpm.2012.0625
    1. Harris K, Li K, Flynn C, et al. . Worst, average or current pain in the brief pain inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol 2007;19:523–7. 10.1016/j.clon.2007.04.007
    1. Koedijk MS, Heijmen BJM, Groot Koerkamp B, et al. . Protocol for the strong trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. BMJ Open 2018;8:e020731. 10.1136/bmjopen-2017-020731
    1. Cleeland CS, Ryan K. The brief pain inventory. pain Research Group, 1991: 143–7.
    1. Health UDo, Services H . Common terminology criteria for adverse events (CTCAE) version 4.0. 4. National Institutes of Health, National Cancer Institute, 2009.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir